ArticleTherapeutic advances in neurological disorders2021

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment.

Navid Manouchehri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.